Comorbidity/Circumstance | Future Research |
---|---|
Cardiovascular disease | Develop risk models for CVD among PsA patients (and patients with inflammatory arthritis in general) |
Examine the effect of therapies on the risk for CV outcomes (ideally in a prospective RCT) | |
Examine the effects of ustekinumab on CV outcomes in PsA patients | |
Examine the safety of biologic DMARD in patients with CHF and PsA | |
Obesity | Define association between obesity and development of PsA and whether this risk is mitigated by weight loss |
Examine the effect of weight loss on disease activity in PsA | |
Examine the safety of MTX and leflunomide in obese patients with PsA | |
Examine the effect of regular exercise on disease activity measures | |
Diabetes | Examine the effect of therapy on blood glucose control in patients with PsA and diabetes |
Examine the effect of optimal glucose control on disease activity in PsA patients | |
Examine the safety of MTX and leflunomide in patients with PsA and diabetes | |
Examine the effect of therapy on the risk for development of diabetes in PsA patients | |
Inflammatory bowel disease | Define association of IBD and PsA in large cohort studies |
Examine appropriate therapy selection for patients with PsA and IBD | |
Ophthalmic disease | Define association of uveitis and PsA in large cohort studies |
Examine appropriate therapy selection for patients with PsA and ophthalmic disease | |
Osteoporosis | Define association of osteoporosis and PsA in large cohort studies |
Examine the effect of therapy for osteoporosis on disease activity in PsA | |
Examine the effect of therapy for PsA on development of osteoporosis | |
Malignancy | Define risk of malignancy (including skin cancer) among PsA patients and better define the risk of malignancy with use of therapies for PsA |
Fatty liver disease | Define the prevalence of fatty liver disease among PsA patients and the association with disease activity |
Examine the effect of therapies for PsA on fatty liver disease | |
Kidney disease | Examine safety of therapies for PsA in patients with chronic kidney disease |
Chronic viral infections | Examine safety of therapies for PsA in patients with chronic HBV, HCV, and HIV |
Vaccinations | Define the best timing and ideal vaccination regimens in patients with PsA |
PsA: psoriatic arthritis; CVD: cardiovascular disease; IBD: inflammatory bowel disease; HBV/HCV: hepatitis B/C virus; HIV: human immunodeficiency virus.